Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

据中央纪委国家监委网站2月26日消息，国家药品监督管理局原党组成员、副局长陈时飞涉嫌严重违纪违法，目前正接受中央纪委国家监委纪律审查和监察调查。陈时飞，男，汉族，1962年7月出生，浙江天台人，1983年8月参加工作，1995年9月加入中国共产党，浙江大学研究生学历，理学博士。

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

Bridgene Biosciences Inc. has signed a strategic collaboration and licensing agreement with Takeda Pharmaceutical Co. Ltd. to discover small-molecule drug candidates against targets in immunology and ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in ...

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) ...

Virginia Cancer Specialists, a respected leader in providing community-based cancer care in Northern VA for more than ...

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Takeda.

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

Nearly four years after signing its first major partnership with Takeda Pharmaceutical Co. Ltd., Bridgene Biosciences Inc. returned for a second deal with Takeda – this time focused on using its ...